icon-folder.gif   Conference Reports for NATAP  
 
  ID Week
Oct 8-12 2014
Philadelphia
Back grey_arrow_rt.gif
 
 
 
HCV Treatment 2014 and Beyond - New Era of Hepatitis C Management
 
 
  from Jules: in his talk Dr Kim reviews new oral HCV therapies & a variety of current issues including study results and cirrhotic and treatment-experienced patients.
 
IDSA: HCV Treatment Cascade: Is Eradication Possible? - Shruti H. Mehta, PhD MPH (10/10/14)
 
Reported by Jules Levin
IDSA, Philadelphia, PA
October 9, 2014
 
Arthur Y. Kim, MD
Massachusetts General Hospital
Harvard Medical School

IDSA1.gif

IDSA2.gif

IDSA3.gif

IDSA4.gif

IDSA5.gif

IDSA6.gif

IDSA7.gif

IDSA8.gif

IDSA9.gif

IDSA10.gif

IDSA11.gif

EASL/2014: Sofosbuvir-Based Regimens Are Associated With High SVR Rates Across Genotypes and Among Patients With Multiple Negative Predictive Factors - (04/14/14)

IDSA12.gif

IDSA13.gif

IDSA14.gif

IDSA15.gif

COSMOS - Simeprevir+Sofosbuvir
 
EASL: Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype-1 prior null responders with METAVIR F0-2: COSMOS study subgroup analysis - (04/14/14)
 
EASL: Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype-1 prior null-responder / treatment-naïve patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3-4 (Cohort 2) - (04/14/14)
 
Janssen Initiates Phase 3 OPTIMIST Trials of Once-Daily Simeprevir in Combination with Once-Daily Sofosbuvir for the Treatment of Genotype 1 Chronic Hepatitis C - (04/03/14)
 
Virology analyses of simeprevir in Phase 2b and 3 studies - (04/17/14)
 
Deep sequencing analyses of minority baseline polymorphisms and persistence of emerging mutations in HCV genotype 1-infected patients treated with simeprevir - (04/17/14)

IDSA16.gif

NEJM - Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection 12, 24 weeks GT1/2/3, FDA Approvals Oct 10 thru Dec This Fall - (10/02/14)

IDSA17.gif

IDSA18.gif

Phase 3 started early 2014
 
Phase III HIV/HCV Co-Infection Daclatasvir (DCV)+ Sofosbuvir (SOF).......in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6)
 
Phase III Daclatasvir + Sofosbuvir in Cirrhotic Subjects and Subjects Post-liver Transplant..
 
Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV
 

IDSA19.gif

IDSA20.gif

IDSA21.gif

IDSA22.gif

EASL: All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With Or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study - (04/14/14)
 
EASL: All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCV-Infected Patients: The Phase 3 ION-2 Study - (04/14/14)
 
EASL: Ledipasvir/Sofosbuvir With and Without Ribavirin for 8 Weeks Compared to Ledipasvir/Sofosbuvir for 12 Weeks in Treatment-Naïve Noncirrhotic Genotype-1 HCV-Infected Patients: The Phase 3 ION-3 Study - (04/11/14)
 
NEJM Publications:
 
ION-1 Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection - (04/14/14)
 
ION-2 Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection - (04/14/14)
 
ION-3 Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis - (04/11/14)
 
The Prevalence of HCV NS5A, Nucleoside and Protease Inhibitor Resistance Associated Variants and the Effects on Treatment with Ledipasvir/Sofosbuvir ± RBV in the Phase 3 ION Studies......"lower SVR rates were not observed in treatment-naive subjects or with longer 24 week LDV/SOF treatment" http://www.natap.org/2014/ResisWksp/ResisWksp_07.htm
 

IDSA23.gif

EASL: TURQUOISE-II: SVR12 RATE OF 92-96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/r/ABT-267 AND ABT-333 PLUS RIBAVIRIN - (04/14/14)
 
NEJM - TURQUOISE-II ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis - Phase 3 TURQUOISE-II - (04/14/14)
 
EASL: SAPPHIRE-I: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 631 TREATMENT-NAïVE ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/11/14)
 
EASL: SAPPHIRE-II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 394 TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/10/14)
 
NEJM Publications:
 
SAPPHIRE-I Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin (in previously untreated patients with HCV genotype 1 infection and no cirrhosis) - (04/11/14)
 
SAPPHIRE-II Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin - (04/10/14) NEJM

IDSA24.gif

IDSA25.gif

IDSA26.gif

Combination Oral, Ribavirin Free, Antiviral Therapy to Optimize Treatment Outcomes for Hepatitis C Treatment Naïve Patients: Interim Results from the NIAID SYNERGY Trial (6 & 12 weeks therapy)......http://www.natap.org/2013/AASLD/AASLD_30.htm

IDSA27.gif

IDSA28.gif

IDSA29.gif

IDSA30.gif